ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors

American Journal of Physiology - Cell Physiology

Volumn 291, Issue 1, 2006, Pages

  Ohtsu, Haruhiko ^a   Dempsey, Peter J ^b   Eguchi, Satoru ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Angiotensin II; Ectodomain shedding

Indexed keywords

ADAM PROTEIN; ANGIOTENSIN II; CHAPERONE; DISINTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; LIGAND; MEMBRANE PROTEIN; MEMBRANE RECEPTOR; METALLOPROTEINASE; UNCLASSIFIED DRUG;

CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; HUMAN; KNOCKOUT MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ADAM PROTEINS; AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; TRANS-ACTIVATION (GENETICS);

EID: 33745714456     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00620.2005     Document Type: Review

References (119)

1. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA, Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze B, Schuster B, Kallen KJ, Saftig P, Rose-John S, and Ludwig A. The transmembrane CXC-chemokine ligand 16 is induced by IFN-γ and TNF-α and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 172: 6362-6372, 2004.
2. Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM, and Courtneidge SA. The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem 278: 16844-16851, 2003.
3. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, and Schlessinger J. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem 276: 20130-20135, 2001.
4. Anliker B and Chun J. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 15: 457-465, 2004.
5. Arasada RR and Carpenter G. Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment. J Biol Chem 280: 30783-30787, 2005.
6. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, and Ishiura S. Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase. Biochem Biophys Res Commun 301: 231-235, 2003.
7. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, and Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40, 2002.
8. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 114: 4143-4151, 2001.
9. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6: 32-43, 2005.
10. Borrell-Pages M, Rojo F, Albanell J, Baselga J, and Arribas J. TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 22: 1114-1124, 2003.
11. Buckley CA, Rouhani FN, Kaler M, Adamik B, Hawari FI, and Levine SJ. Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch. Am J Physiol Lung Cell Mol Physiol 288: L1132-L1138, 2005.
12. Buteau J, Foisy S, Joly E, and Prentki M. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132, 2003.
13. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, and Black RA. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765-27767, 1998.
14. Camden JM, Schrader AM, Camden RE, Gonzalez FA, Erb L, Seye CI, and Weisman GA. P2Y2 nucleotide receptors enhance α-secretase-dependent amyloid precursor protein processing. J Biol Chem 280: 18696-18702, 2005.
15. Citri A, Skaria KB, and Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 284: 54-65, 2003.
16. Daub H, Weiss FU, Wallasch C, and Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379: 557-560, 1996.
17. De Gasparo M, Catt KJ, Inagami T, Wright JW, and Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000.
18. Dempsey PJ, Garton K, and Raines EW. Emerging roles of TACE as a key protease in ErbB ligand shedding. Molec Inter 2: 136-141, 2002.
19. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, and Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 19: 3365-3374, 2000.
20. Diaz-Rodriguez E, Montero JC, Esparis-Ogando A, Yuste L, and Pandiella A. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor α-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell 13: 2031-2044, 2002.
21. Eguchi S, Dempsey PJ, Frank GD, Motley ED, and Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease- dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 276: 7957-7962, 2001.
22. Eguchi S, Frank GD, Mifune M, and Inagami T. Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem Soc Trans 31: 1198-1202, 2003.
23. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, and Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273: 8890-8896, 1998.
24. Fan H, Turck CW, and Derynck R. Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J Biol Chem 278: 18617-18627, 2003.
25. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Cunsolo V, Lauro D, Mauriello A, Smookler DS, Sbraccia P, Sesti G, Lee DC, Khokha R, Accili D, and Lauro R. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-α. J Clin Invest 115: 3494-3505, 2005.
26. Fischer OM, Hart S, Gschwind A, Prenzel N, and Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24: 5172-5183, 2004.
27. Fischer OM, Hart S, Gschwind A, and Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203-1208, 2003.
28. Frank GD and Eguchi S. Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal 5: 771-780, 2003.
29. Frank GD, Mifune M, Inagami T, Ohba M, Sasaki T, Higashiyama S, Dempsey PJ, and Eguchi S. Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: role of metalloprotease and protein kinase C-δ Mol Cell Biol 23: 1581-1589, 2003.
30. 2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 88: 22-29, 2001.
31. Galliano MF, Huet C, Frygelius J, Polgren A, Wewer UM, and Engvall E. Binding of ADAM12, a marker of skeletal muscle regeneration, to the muscle-specific actin-binding protein, α-actinin-2, is required for myoblast fusion. J Biol Chem 275: 13933-13939, 2000.
32. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, and Raines EW. Tumor necrosis factor-α-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276: 37993-38001, 2001.
33. Gonzales PE, Solomon A, Miller AB, Leesnitzer MA, Sagi I, and Milla ME. Inhibition of the tumor necrosis factor-α-converting enzyme by its pro domain. J Biol Chem 279: 31638-31645, 2004.
34. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, and Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 172: 3678-3685, 2004.
35. Griendling KK, Ushio-Fukai M, Lassegue B, and Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29: 366-373, 1997.
36. Gschwind A, Hart S, Fischer OM, and Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22: 2411-2421, 2003.
37. Gschwind A, Zwick E, Prenzel N, Leserer M, and Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20: 1594-1600, 2001.
38. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marme A, Phong MC, Linderkamp O, Skorokhod A, and Altevogt P. Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res 11: 2492-2501, 2005.
39. Hao L, Du M, Lopez-Campistrous A, and Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94: 68-76, 2004.
40. Harris RC, Chung E, and Coffey RJ. EGF receptor ligands. Exp Cell Res 284: 2-13, 2003.
41. Hart S, Fischer OM, Prenzel N, Zwick-Wallasch E, Schneider M, Hennighausen L, and Ullrich A. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol Chem 386: 845-855, 2005.
42. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, Lubke T, Lena Illert A, von Figura K, and Saftig P. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11: 2615-2624, 2002.
43. Hawari FI, Rouhani FN, Cui X, Yu ZX, Buckley C, Kaler M, and Levine SJ. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci USA 101: 1297-1302, 2004.
44. Holbro T and Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217, 2004.
45. Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, Ludwig T, Chiusaroli R, Baron R, Preissner KT, Manova K, and Blobel CP. Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol 23: 5614-5624, 2003.
46. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, and Ortiz RM. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30: 413-422, 2005.
47. 1 integrin-dependent cell spreading. J Cell Biol 149: 1143-1156, 2000.
48. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, and Mekada E. A metalloprotease- disintegrin, MDC9/meltrin-g/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-ancored heparin-binding EGF-like growth factor. EMBO J 17: 7260-7272, 1998.
49. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, and Lee DC. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 22: 2704-2716, 2003.
50. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, and Nikolov DB. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123: 291-304, 2005.
51. Johansson MW, Lye MH, Barthel SR, Duffy AK, Annis DS, and Mosher DF. Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am J Respir Cell Mol Biol 31: 413-422, 2004.
52. King NE, Zimmermann N, Pope SM, Fulkerson PC, Nikolaidis NM, Mishra A, Witte DP, and Rothenberg ME. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol 31: 257-265, 2004.
53. Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, Fujisawa-Sehara A, Ohno S, Suzuki K, and Ishiura S. Membrane-anchored metalloprotease MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein. Biochem J 343: 371-375, 1999.
54. Kranenburg O and Moolenaar WH. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 20: 1540-1546, 2001.
55. Kurisaki T, Masuda A, Sudo K, Sakagami J, Higashiyama S, Matsuda Y, Nagabukuro A, Tsuji A, Nabeshima Y, Asano M, Iwakura Y, and Sehara-Fujisawa A. Phenotypic analysis of meltrin α (ADAM12)-deficient mice: involvement of meltrin α in adipogenesis and myogenesis. Mol Cell Biol 23: 55-61, 2003.
56. Kurohara K, Komatsu K, Kurisaki T, Masuda A, Irie N, Asano M, Sudo K, Nabeshima Y, Iwakura Y, and Sehara-Fujisawa A. Essential roles of meltrin β (ADAM19) in heart development. Dev Biol 267: 14-28, 2004.
57. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, and Fahrenholz F. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927, 1999.
58. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, and Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11: 867-874, 2005.
59. Lemjabbar H and Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 8: 41-46, 2002.
60. Li X and Fan H. Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-α-converting enzyme (TACE). J Biol Chem 279: 27365-27375, 2004.
61. Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, and Lefkowitz RJ. Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem 272: 4637-4644, 1997.
62. Marin V, Montero-Julian F, Gres S, Bongrand P, Farnarier C, and Kaplanski G. Chemotactic agents induce IL-6Rα shedding from polymorphonuclear cells: involvement of a metalloproteinase of the TNF-α-converting enzyme (TACE) type. Eur J Immunol 32: 2965-2970, 2002.
63. McCole DF, Keely SJ, Coffey RJ, and Barrett KE. Transactivation of the epidermal growth factor receptor in colonic epithelial cells by carbachol requires extracellular release of transforming growth factor-α. J Biol Chem 277: 42603-42612, 2002.
64. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, Frank GD, Inagami T, Higashiyama S, Thomas WG, Eckhart AD, Dempsey PJ, and Eguchi S. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 280: 26592-26599, 2005.
65. Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, and Pandiella A. Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci 16: 631-648, 2000.
66. Mori S, Tanaka M, Nanba D, Nishiwaki E, Ishiguro H, Higashiyama S, and Matsuura N. PACSIN3 binds ADAM12/meltrin α and upregulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 278: 46029-46034, 2003.
67. Moss ML and Bartsch JW. Therapeutic benefits from targeting of ADAM family members. Biochemistry 43: 7227-7235, 2004.
68. 2+ influx and PKC activation. J Cell Biol 165: 893-902, 2004.
69. Ni CY, Murphy MP, Golde TE, and Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181, 2001.
70. Ohtsu H, Frank GD, Utsunomiya H, and Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid Redox Signal 7: 1315-1326, 2005.
71. Ohtsu H, Nakashima H, Suzuki H, Eguchi K, Higuchi S, Inagami T, Frank GD, and Eguchi S. ADAM17/TACE mediates HB-EGF shedding and EGF receptor transactivation by angiotensin II in vascular smooth muscle cells (Abstract). Hypertension 46: 821, 2005.
72. Olivares-Reyes JA, Shah BH, Hernandez-Aranda J, Garcia-Caballero A, Farshori MP, Garcia-Sainz JA, and Catt KJ. Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Mol Pharmacol 68: 356-364, 2005.
73. Peduto L, Reuter VE, Shaffer DR, Scher HI, and Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res 65: 9312-9319, 2005.
74. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, and Black RA. An essential role for ectodomain shedding in mammalian development. Science 282: 1281-1284, 1998.
75. Pierce KL, Luttrell LM, and Lefkowitz RJ. New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20: 1532-1539, 2001.
76. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, and Lefkowitz RJ. Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J Biol Chem 276: 23155-23160, 2001.
77. Pietri M, Schneider B, Mouillet-Richard S, Ermonval M, Mutel V, Launay JM, and Kellermann O. Reactive oxygen species-dependent TNF-α converting enzyme activation through stimulation of 5-HT2B and α1D autoreceptors in neuronal cells. FASEB J 19: 1078-1087, 2005.
78. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, and Fahrenholz F. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456-1464, 2004.
79. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, and Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888, 1999
80. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, and Black RA. Functional analysis of the domain structure of tumor necrosis factor-α converting enzyme. J Biol Chem 275: 14608-14614, 2000.
81. Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F, and Gudermann T. Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 278: 47307-47318, 2003.
82. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, and Blobel CP. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769-779, 2004.
83. Saito S, Frank GD, Motley ED, Dempsey PJ, Utsunomiya H, Inagami T, and Eguchi S. Metalloprotease inhibitor blocks angiotensin II-induced migration through inhibition of epidermal growth factor receptor transactivation. Biochem Biophys Res Commun 294: 1023-1029, 2002.
84. Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, Raines EW, Dunbar AJ, and Dempsey PJ. ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 280: 1826-1837, 2005.
85. Schafer B, Gschwind A, and Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23: 991-999, 2004.
86. Schafer B, Marg B, Gschwind A, and Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 279: 47929-47938, 2004.
87. Seals DF and Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30, 2003.
88. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91: 406-413, 2002.
89. Seta K and Sadoshima J. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced transactivation of the epidermal growth factor receptor. J Biol Chem 278: 9019-9026, 2003.
90. Shah BH and Catt KJ. Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy. Trends Endocrinol Metab 15: 241-243, 2004.
91. Shah BH, Farshori MP, Jambusaria A, and Catt KJ. Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem 278: 19118-19126, 2003.
92. Shah BH, Yesilkaya A, Olivares-Reyes JA, Chen HD, Hunyady L, and Catt KJ. Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol Endocrinol 18: 2035-2048, 2004.
93. 735 in TNFα-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 118: 2371-2380, 2005.
94. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, and Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development 132: 3923-3933, 2005.
95. Suzuki H, Motley ED, Frank GD, Utsunimiya H, and Eguchi S. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction, and structural requirement. Curr Med Chem 3: 305-322, 2005.
96. Suzuki M, Raab G, Moses MA, Fernandez CA, and Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272: 31730-31737, 1997.
97. Sweeney C and Carraway KL 3rd. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19: 5568-5573, 2000.
98. Tanaka M, Nanba D, Mori S, Shiba F, Ishiguro H, Yoshino K, Matsuura N, and Higashiyama S. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 279: 41950-41959, 2004.
99. Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, Ohara H, Nakazawa T, Nomura T, Kinugasa Y, Ohmoto H, Ishiguro H, Yoshino K, Higashiyama S, and Itoh M. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 127: 559-569, 2004.
100. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, and Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90: 135-142, 2002.
101. Togashi N, Ura N, Higashiura K, Murakami H, and Shimamoto K. Effect of TNF-α-converting enzyme inhibitor on insulin resistance in fructose-fed rats. Hypertension 39: 578-580, 2002.
102. Touyz RM and Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 52: 639-672, 2000.
103. Tsai W, Morielli AD, and Peralta EG. The m1 muscarinic acetylcholine receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J 16: 4597-4605, 1997.
104. Tsou CL, Haskell CA, and Charo IF. Tumor necrosis factor-α- converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 276: 44622-44626, 2001.
105. Umata T, Hirata M, Takahashi T, Ryu F, Shida S, Takahashi Y, Tsuneoka M, Miura Y, Masuda M, Horiguchi Y, and Mekada E. A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 276: 30475-30482, 2001.
106. Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, and Alexander RW. cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ Res 97: 829-836, 2005.
107. Van Eerdewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit S, McKenny J, Braunschweiger K, Walsh A, Liu Z, Hayward B, Folz C, Manning SP, Bawa A, Saracino L, Thackston M, Benchekroun Y, Capparell N, Wang M, Adair R, Feng Y, Dubois J, FitzGerald MG, Huang H, Gibson R, Allen KM, Pedan A, Danzig MR, Umland SP, Egan RW, Cuss FM, Rorke S, Clough JB, Holloway JW, Holgate ST, and Keith TP. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418: 426-430, 2002.
108. Wakatsuki S, Kurisaki T, and Sehara-Fujisawa A. Lipid rafts identified as locations of ectodomain shedding mediated by meltrin β/ADAM19. J Neurochem 89: 119-123, 2004.
109. White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 15: 598-606, 2003.
110. Wolfe MS and Kopan R. Intramembrane proteolysis: theme and variations. Science 305: 1119-1123, 2004.
111. Wu E, Croucher PI, and McKie N. Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun 235: 437-442, 1997.
112. Yan Y, Shirakabe K, and Werb Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 158: 221-226, 2002.
113. Yin G, Yan C, and Berk BC. Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 35: 780-783, 2003.
114. Yu WH, Woessner JF Jr, McNeish JD, and Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16: 307-323, 2002.
115. Zhang Z, Oliver P, Lancaster JJ, Schwarzenberger PO, Joshi MS, Cork J, and Kolls JK. Reactive oxygen species mediate tumor necrosis factor α-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 15: 303-305, 2001.
116. Zhao J, Chen H, Peschon JJ, Shi W, Zhang Y, Frank SJ, and Warburton D. Pulmonary hypoplasia in mice lacking tumor necrosis factor-α converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol 232: 204-218, 2001.
117. Zheng Y, Schlondorff J, and Blobel CP. Evidence for regulation of the tumor necrosis factor α-convertase (TACE) by protein-tyrosine phosphatase PTPH1. J Biol Chem 277: 42463-42470, 2002.
118. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, and Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 25: 1824-1830, 2005.
119. Zwick E, Daub H, Aoki N, Yamaguchi-Aoki Y, Tinhofer I, Maly K, and Ullrich A. Critical role of calcium-dependent epidermal growth factor receptor transactivation in PC12 cell membrane depolarization and bradykinin signaling. J Biol Chem 272: 24767-24770, 1997.